Skip to main content

Table 1 Characteristics of the studies included in this meta-analysis

From: Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis

Authors/year of publication

Country

Male (%)

Mean age

Intervention

Follow-up

Study design

Outcomes assessed

Stem cell

Control

Seth/2010 [20]

India

83.9

Stem cell: 45 ± 15 years

Control: 49 ± 9 years

41

40

36 M

RCT

Mortality, LVEF, LVEDCS, and LVESV

Vrtovec/2011 [14]

USA

79

53 ± 9 years

28

27

12 M

RCT

Mortality, LVEF, LVEDCS, and 6-min-walk test

Vrtovec/2013 [21]

USA

81

54 ± 9 years

55

55

60 M

RCT

Mortality, LVEF, LVEDCS, and 6-min-walk test

Henry/2014 [22]

USA

68.9

Stem cell: 57.9 ± 11 years

Control: 52.3 ± 11 years

18

11

12 M

RCT

Mortality, LVEF, LVESV, and 6-min-walk test

Sant Anna/2014 [23]

Brazil

60

Stem cell: 48.3 ± 8.71 years

Control: 51.6 ± 7.79 years

20

10

12 M

RCT

Mortality, LVEF, LVESV, LVEDCS, and 6-min-walk test

Hamshere/2015 [26]

UK

75.8

Stem cell: 57.67 ± 12.32 years

Control: 56.79 ± 9.84 years

15

14

12 M

RCT

Mortality, LVEF, LVEDCS, and LVESV

Martino/2015 [24]

Brazil

70.6

Stem cell: 51 ± 11.1 years

Control: 49.6 ± 11.1 years

82

78

12 M

RCT

Mortality, LVEF, LVESV, and 6-min-walk test

Xiao/2017 [25]

China

75.6

Stem cell: 51.6 ± 12.2 years

Control: 54.4 ± 11.6 years

17

20

12 M

RCT

Mortality, LVEF, LVEDCS, and 6-min-walk test

  1. LVEDCS left ventricular end-diastolic chamber size, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, M months, NA not available, RCT randomized controlled trial